Last reviewed · How we verify
Omega-3 Fatty Acid Supplement
At a glance
| Generic name | Omega-3 Fatty Acid Supplement |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery (NA)
- Preoperative Fish Oil PN and Prognosis After Constipation Surgery
- Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms (EARLY_PHASE1)
- Long-Term Omega-3 and Omega-3 Index >8%: Effects on Physiological Recovery (NA)
- Marine Lipids Ease Painful TMD (NA)
- Omega-3 Supplementation for Pediatric Migraine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega-3 Fatty Acid Supplement CI brief — competitive landscape report
- Omega-3 Fatty Acid Supplement updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI